Literature DB >> 31343664

Assessment of Deep Natural Language Processing in Ascertaining Oncologic Outcomes From Radiology Reports.

Kenneth L Kehl1,2,3, Haitham Elmarakeby3, Mizuki Nishino4, Eliezer M Van Allen3, Eva M Lepisto1,3,5, Michael J Hassett1,3, Bruce E Johnson2,3, Deborah Schrag1,3.   

Abstract

IMPORTANCE: A rapid learning health care system for oncology will require scalable methods for extracting clinical end points from electronic health records (EHRs). Outside of clinical trials, end points such as cancer progression and response are not routinely encoded into structured data.
OBJECTIVE: To determine whether deep natural language processing can extract relevant cancer outcomes from radiologic reports, a ubiquitous but unstructured EHR data source. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study evaluated 1112 patients who underwent tumor genotyping for a diagnosis of lung cancer and participated in the Dana-Farber Cancer Institute PROFILE study from June 26, 2013, to July 2, 2018. EXPOSURES: Patients were divided into curation and reserve sets. Human abstractors applied a structured framework to radiologic reports for the curation set to ascertain the presence of cancer and changes in cancer status over time (ie, worsening/progressing vs improving/responding). Deep learning models were then trained to capture these outcomes from report text and subsequently evaluated in a 10% held-out test subset of curation patients. Cox proportional hazards regression models compared human and machine curations of disease-free survival, progression-free survival, and time to improvement/response in the curation set, and measured associations between report classification and overall survival in the curation and reserve sets. MAIN OUTCOMES AND MEASURES: The primary outcome was area under the receiver operating characteristic curve (AUC) for deep learning models; secondary outcomes were time to improvement/response, disease-free survival, progression-free survival, and overall survival.
RESULTS: A total of 2406 patients were included (mean [SD] age, 66.5 [10.8] years; 1428 female [59.7%]; 2170 [90.2%] white). Radiologic reports (n = 14 230) were manually reviewed for 1112 patients in the curation set. In the test subset (n = 109), deep learning models identified the presence of cancer, improvement/response, and worsening/progression with accurate discrimination (AUC >0.90). Machine and human curation yielded similar measurements of disease-free survival (hazard ratio [HR] for machine vs human curation, 1.18; 95% CI, 0.71-1.95); progression-free survival (HR, 1.11; 95% CI, 0.71-1.71); and time to improvement/response (HR, 1.03; 95% CI, 0.65-1.64). Among 15 000 additional reports for 1294 reserve set patients, algorithm-detected cancer worsening/progression was associated with decreased overall survival (HR for mortality, 4.04; 95% CI, 2.78-5.85), and improvement/response was associated with increased overall survival (HR, 0.41; 95% CI, 0.22-0.77). CONCLUSIONS AND RELEVANCE: Deep natural language processing appears to speed curation of relevant cancer outcomes and facilitate rapid learning from EHR data.

Entities:  

Year:  2019        PMID: 31343664      PMCID: PMC6659158          DOI: 10.1001/jamaoncol.2019.1800

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


  35 in total

Review 1.  Evolution of Hematology Clinical Trial Adverse Event Reporting to Improve Care Delivery.

Authors:  Tamara P Miller; Richard Aplenc
Journal:  Curr Hematol Malig Rep       Date:  2021-03-30       Impact factor: 3.952

2.  Deep Learning-based Assessment of Oncologic Outcomes from Natural Language Processing of Structured Radiology Reports.

Authors:  Matthias A Fink; Klaus Kades; Arved Bischoff; Martin Moll; Merle Schnell; Maike Küchler; Gregor Köhler; Jan Sellner; Claus Peter Heussel; Hans-Ulrich Kauczor; Heinz-Peter Schlemmer; Klaus Maier-Hein; Tim F Weber; Jens Kleesiek
Journal:  Radiol Artif Intell       Date:  2022-07-20

3.  Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade.

Authors:  Kathryn C Arbour; Anh Tuan Luu; Jia Luo; Justin F Gainor; Regina Barzilay; Matthew D Hellmann; Hira Rizvi; Andrew J Plodkowski; Mustafa Sakhi; Kevin B Huang; Subba R Digumarthy; Michelle S Ginsberg; Jeffrey Girshman; Mark G Kris; Gregory J Riely; Adam Yala
Journal:  Cancer Discov       Date:  2020-09-21       Impact factor: 39.397

4.  Natural Language Processing to Ascertain Cancer Outcomes From Medical Oncologist Notes.

Authors:  Kenneth L Kehl; Wenxin Xu; Eva Lepisto; Haitham Elmarakeby; Michael J Hassett; Eliezer M Van Allen; Bruce E Johnson; Deborah Schrag
Journal:  JCO Clin Cancer Inform       Date:  2020-08

5.  Automated NLP Extraction of Clinical Rationale for Treatment Discontinuation in Breast Cancer.

Authors:  Matthew S Alkaitis; Monica N Agrawal; Gregory J Riely; Pedram Razavi; David Sontag
Journal:  JCO Clin Cancer Inform       Date:  2021-05

6.  FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma.

Authors:  James M Cleary; Srivatsan Raghavan; Qibiao Wu; Yvonne Y Li; Liam F Spurr; Hersh V Gupta; Douglas A Rubinson; Isobel J Fetter; Jason L Hornick; Jonathan A Nowak; Giulia Siravegna; Lipika Goyal; Lei Shi; Lauren K Brais; Maureen Loftus; Atul B Shinagare; Thomas A Abrams; Thomas E Clancy; Jiping Wang; Anuj K Patel; Franck Brichory; Anne Vaslin Chessex; Ryan J Sullivan; Rachel B Keller; Sarah Denning; Emma R Hill; Geoffrey I Shapiro; Anna Pokorska-Bocci; Claudio Zanna; Kimmie Ng; Deborah Schrag; Pasi A Jänne; William C Hahn; Andrew D Cherniack; Ryan B Corcoran; Matthew Meyerson; Antoine Daina; Vincent Zoete; Nabeel Bardeesy; Brian M Wolpin
Journal:  Cancer Discov       Date:  2021-04-29       Impact factor: 39.397

Review 7.  Artificial intelligence in oncology: Path to implementation.

Authors:  Isaac S Chua; Michal Gaziel-Yablowitz; Zfania T Korach; Kenneth L Kehl; Nathan A Levitan; Yull E Arriaga; Gretchen P Jackson; David W Bates; Michael Hassett
Journal:  Cancer Med       Date:  2021-05-07       Impact factor: 4.452

8.  Accelerating precision medicine in metastatic prostate cancer.

Authors:  Joaquin Mateo; Rana McKay; Wassim Abida; Rahul Aggarwal; Joshi Alumkal; Ajjai Alva; Felix Feng; Xin Gao; Julie Graff; Maha Hussain; Fatima Karzai; Bruce Montgomery; William Oh; Vaibhav Patel; Dana Rathkopf; Matthew Rettig; Nikolaus Schultz; Matthew Smith; David Solit; Cora Sternberg; Eliezer Van Allen; David VanderWeele; Jake Vinson; Howard R Soule; Arul Chinnaiyan; Eric Small; Jonathan W Simons; William Dahut; Andrea K Miyahira; Himisha Beltran
Journal:  Nat Cancer       Date:  2020-11-17

9.  Clinical Inflection Point Detection on the Basis of EHR Data to Identify Clinical Trial-Ready Patients With Cancer.

Authors:  Kenneth L Kehl; Stefan Groha; Eva M Lepisto; Haitham Elmarakeby; James Lindsay; Alexander Gusev; Eliezer M Van Allen; Michael J Hassett; Deborah Schrag
Journal:  JCO Clin Cancer Inform       Date:  2021-06

10.  Patterns of Metastatic Disease in Patients with Cancer Derived from Natural Language Processing of Structured CT Radiology Reports over a 10-year Period.

Authors:  Richard K G Do; Kaelan Lupton; Pamela I Causa Andrieu; Anisha Luthra; Michio Taya; Karen Batch; Huy Nguyen; Prachi Rahurkar; Lior Gazit; Kevin Nicholas; Christopher J Fong; Natalie Gangai; Nikolaus Schultz; Farhana Zulkernine; Varadan Sevilimedu; Krishna Juluru; Amber Simpson; Hedvig Hricak
Journal:  Radiology       Date:  2021-08-03       Impact factor: 29.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.